NCT05651074招募中1 期
A Pharmacokinetic/Pharmacodynamic Study to Evaluate the Effect of Omeprazole of Vicagrel in Healthy Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Inhibition of platelet aggregation [IPA] evaluated in healthy subjects to treatment with vicagrel
研究概览
简要总结
The primary objective of the study is to evaluate the effects of omeprazole on the PK and PD of a single dose of vicagrel in healthy subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Able and willing to give written informed consent before study, and fully understand the study content, process and possible adverse reactions;
- •Able to complete the study in compliance with the protocol;
- •Subject (including partner) is willing to voluntarily take effective contraceptive measures from screening through 6 months after the last dose of study drug (see Appendix 5 for details);
- •Male and female subjects between the ages of 18 and 45 years, inclusive;
- •At least 50 kg for male subjects, 45 kg for female subjects, with a Body Mass Index (BMI= Weight/Height2) between 18-28 kg/m2, inclusive;
- •With normal or clinically insignificant abnormal results of physical examination and vital signs test;
- •CYP2C19 normal metabolizers (CYP2C19*1/*1).
排除标准
- •More than 5 cigarettes per day on average within 3 months before the study;
- •History of sensitivity to drugs similar to the study drug or have high sensitivity to clopidogrel, or hypersensitivity to omeprazole, other benzimidazoles, or any excipients, allergic constitution (e.g. allergy to various drugs and foods);
- •History of drug abuse, drug use, alcohol abuse (14 units of alcohol per week: 1 unit = 285 mL beer, 25 mL spirit or 100 mL wines);
- •Donation or loss of a significant volume of blood (> 450 mL) within 3 months prior to screening;
- •Intake of any prescription drugs, over-the-counter drugs, vitamin or herbal medicine within 14 days prior to receiving study drug;
- •Consumption of any special diet (such as grapefruit, pitaya, mango, pomelo, etc.) or subjects have engaged strenuous exercise or any other factors affecting drug absorption, distribution, metabolism and excretion within 14 days prior to receiving study drug;
- •Intake of any drug which Have taken strong inhibitors and/or inducers of liver metabolic enzymes (CYP1A2, 2A6, 2C8, 2C19, 3A4 and 3A5) within 28 days before the first medication, and strong inhibitors of liver metabolic enzymes such as: ciprofloxacin, clopidogrel, Itraconazole, ketoconazole, ritonavir, troleandomycin, etc., strong inducers of liver metabolism enzymes such as: rifampicin, carbamazepine, phenytoin sodium, St. John's wort, etc. (For details see Appendix 6);
- •Recent major changes in diet or exercise habits;
- •Use of an investigational drug or product, or participation in a drug research study within 3 months prior to receiving study drug;
- •History of difficulties in swallowing, or any gastrointestinal disease which could affect the drug absorption;
- •Suffering from any diseases that may increase the risk of bleeding, such as hemorrhoids, acute gastritis, stomach and duodenal ulcers, Thrombocytopenic Purpura and hemophilia, etc;
- •Family history of coagulation or bleeding disorders (e.g., hemophilia)/symptoms (e.g., vomiting blood, black stools, severe or recurrent nosebleeds, coughing up blood, significant hematuria, or intracranial hemorrhage) or suspected vascular malformations, such as aneurysms or early onset strokes, in the individual or in their immediate family;
- •A clinically significant 12-lead ECG abnormality;
- •Positive test results of blood pregnancy or subject is lactating for female subjects;
- •Any clinically significant abnormalities/findings in laboratory tests, or any clinically significant disease including but not limited to gastrointestinal, renal, hepatic, neurological system, blood, endocrine, tumor, lung, immune, mental, or cardiovascular and cerebrovascular diseases;
- •Positive test results for viral hepatitis (including hepatitis B and C), HIV antibody or syphilis antibody;
- •Acute illness or concomitant medication from screening to the first dosing of study medication;
- •Consumption of chocolate or any food or beverages containing caffeine or (rich containing) xanthine within 48 h prior to receiving the first dosing of study medication;
- •Consumption of any product containing alcohol within 24 h prior to receiving the first dosing of study medication, or positive results from a screen for alcohol;
- •Positive results from a screen for urine drug test (Morphine, marijuana);
- •Subjects were vaccinated within 4 weeks prior to screening, or planned to be vaccinated during the trial;
- •Any condition which in the opinion of Investigator is not suitable for subjects to participate in the study.
研究组 & 干预措施
Vicagrel and omeprazole
Experimental
D1 single dose of vicagrel was administered. Omeprazole administration was started on D4, once daily for 5 days, and a single dose of vicagrel and omeprazole coadministration on day 9.
干预措施: Vicagrel and omeprazole (Drug)
结局指标
主要结局
Inhibition of platelet aggregation [IPA] evaluated in healthy subjects to treatment with vicagrel
时间窗: Day 2 of each period
Platelet reactivity index [PRI] evaluated in healthy subjects to treatment with vicagrel
时间窗: Day 2 of each period
Area under the concentration-time curve (AUC)
时间窗: Up to 48 hours postdose on Day 3 for each period
maximum plasma concentration (Cmax)
时间窗: Up to 48 hours postdose on Day 3 for each period
次要结局
- Assess the safety of a single dose of vicagrel and a combination of vicagrel and omeprazole in healthy subjects by assessment of adverse events and symptoms and physical examination, clinical laboratory tests, vital signs,12-ECG.(Day1-Day11)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Effects of omeprazole on the pharmacokinetics of irinotecan in cancer patients.Cancer.NL-OMON28883Erasmus MC - Afdeling Interne Oncologie14
Unknown
4 期
Research of Efficient Use of Omeprazole in Combination With Domperidone in Gastroesophageal Reflux Disease of Mild to Moderate SeverityGERDNCT02140073Belarusian Medical Academy of Post-Graduate Education60
已完成
1 期
A Study to Evaluate the Effects of Food and Esomeprazole on the Pharmacokinetics of Crizotinib in a Coated Microsphere Formulation.HealthyNCT03137134Pfizer18
终止
1 期
High Dose Omeprazole in Patients With Pancreatic CancerExocrine Pancreatic CancerNCT04930991University of Oklahoma25
已完成
3 期
A Study to Investigate the Pharmacodynamic Effect After Four-week Omeprazole Treatment of Non-erosive Reflux Disease in a Japanese PopulationNon-erosive Reflux DiseaseNCT00259051AstraZeneca40